According to Fortune Business Insights, the global A2A agonists market was valued at USD 0.35 billion in 2025. The market is projected to grow from USD 0.41 billion in 2026 to USD 1.40 billion by 2034, exhibiting a CAGR of 14.6% during the forecast period from 2026 to 2034. The market is a niche but clinically important segment within cardiovascular diagnostics and drug development, with regadenoson-based injectable products currently leading commercial demand.
The A2A agonists market is currently concentrated around intravenous regadenoson products. These products are used as pharmacologic stress agents during radionuclide myocardial perfusion imaging, particularly for patients who cannot undergo adequate exercise stress.
Growth is being supported by the rising use of non-invasive cardiac imaging, increasing diagnosis of coronary artery disease, regulatory approvals, new product launches, and partnerships among market participants. Research into A2A receptor biology may also create opportunities beyond cardiovascular diagnostics, including potential applications in inflammation, tissue protection, wound healing, and pain-related indications.
For example, in August 2024, Indies Pharma received a New Drug Application from the U.S. FDA for Regadenoson injection 0.4 mg/5 mL single-dose pre-filled syringe for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.
For detailed market insights: https://www.fortunebusinessinsights.com/a2a-agonists-market-119209
One of the major trends in the A2A agonists market is the expansion of regadenoson beyond traditional SPECT myocardial perfusion imaging. Its use in additional cardiac imaging modalities can broaden the potential applications of pharmacologic stress testing.
Another important trend is the increasing availability of generic regadenoson injections. Generic products can improve accessibility and strengthen procurement opportunities for healthcare institutions.
Product launches are also influencing the market. In March 2023, Meitheal Pharmaceuticals launched Regadenoson Injection 0.4 mg/5 mL pre-filled syringe for use as a pharmacologic stress agent during radionuclide myocardial perfusion imaging.
The growing burden of cardiovascular diseases is a major factor driving the A2A agonists market. Many patients with suspected coronary artery disease are elderly, physically limited, or unable to complete adequate exercise stress testing. This creates demand for pharmacological alternatives that can support cardiac evaluation.
Regadenoson-based A2A agonists are consequently gaining importance in hospitals, diagnostic imaging centers, and nuclear cardiology laboratories. The increasing need for accurate and non-invasive cardiac assessment is expected to sustain demand throughout the forecast period.
The increasing use of advanced cardiac imaging is another growth driver. In February 2022, GE HealthCare received European Commission approval for Rapiscan (regadenoson) to be used in additional imaging modalities, including stress cardiac magnetic resonance imaging. This expanded its role beyond SPECT myocardial perfusion imaging and supported broader use of pharmacologic stress testing.
Safety concerns associated with pharmacologic cardiac stress agents may restrain wider adoption. Regadenoson increases coronary blood flow, but its pharmacological effects can create risks in patients with unstable cardiac conditions. Therefore, appropriate patient screening, trained healthcare personnel, monitoring, and access to resuscitation equipment are important during administration.
A 2025 JACC Case Reports publication highlighted four cases involving ST-segment elevation myocardial infarction or STEMI-equivalent events following intravenous regadenoson administration during pharmacologic radionuclide myocardial perfusion imaging. Such concerns may limit product use among certain high-risk cardiac patients.